Impact of Lipoprotein (a) on Long-Term Outcomes in Patients With Acute Myocardial Infarction
-
- Dai Kazuoki
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital
-
- Shiode Nobuo
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital
-
- Yoshii Kanade
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital
-
- Kimura Yuka
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital
-
- Matsuo Keita
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital
-
- Jyuri Yusuke
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital
-
- Tomomori Shunsuke
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital
-
- Higaki Tadanao
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital
-
- Oi Kuniomi
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital
-
- Kawase Tomoharu
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital
-
- Sairaku Akinori
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital
-
- Ohashi Norihiko
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital
-
- Suenari Kazuyoshi
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital
-
- Nishioka Kenji
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital
-
- Masaoka Yoshiko
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital
-
- Nakano Yukiko
- Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences
この論文をさがす
抄録
<p>Background: Lipoprotein (a) (Lp(a)) is a complex circulating lipoprotein, and there is increasing evidence it is a risk factor for atherosclerotic cardiovascular disease (ASCVD). This study aimed to investigate the influence of Lp(a) serum levels on long-term outcomes after acute myocardial infarction (AMI).</p><p>Methods and Results: Between January 2015 and January 2018, we enrolled 262 patients with AMI who underwent coronary angiography within 24 h of the onset of chest pain and had available Lp(a) data enabling subdivision into 2 groups: high Lp(a) (≥32 mg/dL: n=76) and low Lp(a) (<32 mg/dL: n=186). The primary endpoint was major adverse cardiac events (MACE), which was defined as a composite of cardiac death, nonfatal MI, and readmission for heart failure. Multivariate Cox regression analysis was performed to identify the predictors of MACE. The incidence of MACE was significantly higher in the high Lp(a) group than in the low Lp(a) group (32.8% vs. 19.6%, P=0.004). Multivariate analysis showed that Lp(a) ≥32 mg/dL was an independent predictor of MACE (hazard ratio 2.84, 95% confidence interval 1.25–6.60, P=0.013).</p><p>Conclusions: High Lp(a) levels were associated with worse long-term outcomes after AMI, so Lp(a) may be useful for risk assessment.</p>
収録刊行物
-
- Circulation Journal
-
Circulation Journal 87 (10), 1356-1361, 2023-09-25
一般社団法人 日本循環器学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390860532056050688
-
- NII書誌ID
- AA11591968
-
- ISSN
- 13474820
- 13469843
-
- NDL書誌ID
- 033087053
-
- PubMed
- 37258219
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
-
- 抄録ライセンスフラグ
- 使用不可